Disease · EFO_1001461
endothelial dysfunction
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. endothelial dysfunction. Diseases, record EFO_1001461. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001461
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- endothelial dysfunction
- Open Targets ID
- EFO_1001461
- Highest stage of its drugs
- Phase 3, for 10 of its 56 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs56
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| ATORVASTATIN | CHEMBL1487 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ALLOPURINOL | CHEMBL1467 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACARBOSE | CHEMBL404271 | Oligosaccharide | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ERGOCALCIFEROL | CHEMBL1536 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GLICLAZIDE | CHEMBL427216 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LINAGLIPTIN | CHEMBL237500 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LIPOIC ACID, ALPHA | CHEMBL33864 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| METFORMIN | CHEMBL1431 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| POLICOSANOL | CHEMBL3707352 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PROBENECID | CHEMBL897 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 56
See all 56 drugsTargets116
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| PDE5A | 3',5'-cyclic phosphodiesterase | 4 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 5A inhibitor | Phase 2 | https://conductscience.org/library/genes/8654 | Drugs and targets |
| ADRA1A | Adrenergic receptor alpha-1 | 2 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/148 | Drugs and targets |
| ADRA1B | Adrenergic receptor alpha-1 | 2 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/147 | Drugs and targets |
| ADRA1D | Adrenergic receptor alpha-1 | 2 | Adrenergic receptor alpha-1 antagonist | Unknown | https://conductscience.org/library/genes/146 | Drugs and targets |
| CACNA1C | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/775 | Drugs and targets |
| CACNA1D | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/776 | Drugs and targets |
| CACNA1F | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/778 | Drugs and targets |
| CACNA1S | Voltage-gated L-type calcium channel | 2 | Voltage-gated L-type calcium channel blocker | Phase 2 | https://conductscience.org/library/genes/779 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 2 | Dipeptidyl peptidase IV inhibitor | Phase 3 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| HMGCR | 3-hydroxy-3-methylglutaryl-coenzyme A reductase | 2 | HMG-CoA reductase inhibitor | Phase 3 | https://conductscience.org/library/genes/3156 | Drugs and targets |
1 to 10 of 116
See all 116 targetsTrials52
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01320722 | Study of Vitamin D and Uric Acid Lowering on Kidney and Blood Vessel Function | Phase 3 | 242 | 2017-06-29 | Renal Function, Endothelial Function, Blood Pressure, Overweight, Obesity | ALLOPURINOL, ERGOCALCIFEROL, PROBENECID | Its record names the disease | ClinicalTrials.gov |
| NCT03837626 | ENAC Blockade and Arterial Stiffness | Phase 2/3 | 137 | 2025-12-30 | Overweight and Obesity, Insulin Resistance | AMILORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01426438 | Endothelial Function, Lipoproteins, and Inflammation With Low HDL Cholesterol in HIV: ER Niacin Versus Fenofibrate | Phase 2 | 99 | 2014-10-21 | HIV-1 Infection | FENOFIBRATE, NIACIN, SITAGLIPTIN | Its record names the disease | ClinicalTrials.gov |
| NCT00532844 | A Phase 2, Pharmacokinetic (PK) Study of 6R-BH4 Alone or 6R-BH4 With Vitamin C in Subjects With Endothelial Dysfunction | Phase 2 | 52 | 2021-05-17 | Endothelial Dysfunction | SAPROPTERIN DIHYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00417170 | Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome | Phase 2 | 48 | 2011-08-11 | High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction | ALISKIREN, AMLODIPINE | Its record names the disease | ClinicalTrials.gov |
| NCT01334554 | Study of Sildenafil Citrate on Insulin Resistance in African American | Phase 1/2 | 46 | 2015-04-10 | Metabolic Syndrome, Obesity | SILDENAFIL CITRATE | Its record names the disease | ClinicalTrials.gov |
| NCT02280655 | Adverse Effects of Red Blood Cell Transfusions: A Unifying Hypothesis (Aim 3) | Phase 2 | 43 | 2014-12-04 | Cardiovascular Diseases | BLOOD CELLS, RED | Its record names the disease | ClinicalTrials.gov |
| NCT00965185 | Statin Therapy to Improve Atherosclerosis in HIV Patients | Not applicable | 40 | 2015-02-26 | Cardiovascular Disease, HIV, Atherosclerosis, Inflammation, Statins, HMG-CoA, HIV Infections | ATORVASTATIN | Its record names the disease | ClinicalTrials.gov |
| NCT02406586 | Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2) | Not applicable | 36 | 2015-05-28 | Hypertension, Diabetes | CARVEDILOL, SALSALATE | Its record names the disease | ClinicalTrials.gov |
| NCT01216735 | Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers | Not applicable | 32 | 2014-12-05 | Tobacco Abuse Smoke | FLUTICASONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 52
See all 52 trialsComparisons in its trials16
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Amiloride vs Placebo: deaths from any cause | 0 of 90 | 0 of 47 | 137 | NCT03837626 | Trial comparisons |
| Amiloride vs Placebo: serious adverse events | 0 of 90 | 0 of 47 | 137 | NCT03837626 | Trial comparisons |
| Sapropterin Dihydrochloride 10mg/kg vs Sapropterin Dihydrochloride 10mg/kg and Vitamin C: deaths from any cause | 0 of 49 | 0 of 50 | 99 | NCT00532844 | Trial comparisons |
| Sapropterin Dihydrochloride 10mg/kg vs Sapropterin Dihydrochloride 10mg/kg and Vitamin C: serious adverse events | 0 of 49 | 0 of 50 | 99 | NCT00532844 | Trial comparisons |
| Arm A: Extended-release Niacin With Aspirin vs Arm B: Fenofibrate: serious adverse events | 1 of 50 | 0 of 49 | 99 | NCT01426438 | Trial comparisons |
| Aliskiren 300mg vs Amlodipine 5mg: serious adverse events | 0 of 23 | 0 of 25 | 48 | NCT00417170 | Trial comparisons |
| Sildenafil vs Placebo: serious adverse events | 0 of 23 | 0 of 23 | 46 | NCT01334554 | Trial comparisons |
| Storage-aged Red Blood Cells (saRBCs) vs Fresh Red Blood Cells (RBCs): serious adverse events | 0 of 25 | 0 of 18 | 43 | NCT02280655 | Trial comparisons |
| Atorvastatin vs Placebo: Liver Function Tests (LFTs) | 3 of 19 | 2 of 21 | 40 | NCT00965185 | Trial comparisons |
| Atorvastatin vs Placebo: serious adverse events | 2 of 19 | 1 of 21 | 40 | NCT00965185 | Trial comparisons |
1 to 10 of 16
See all 16 comparisons in its trialsPapers from its trials48
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001461
GET https://conductscience.org/api/diseases/v1/EFO_1001461/drugs?page=2